Yellow tape measure with a variety of weight loss medication on blue background
Biotech

Kailera’s oral GLP-1 asset hits goals in Chinese phase 3 trials

The readouts position Kailera’s partner Hengrui Pharma to seek approval in obesity and diabetes in China.
Nick Paul Taylor Jul 7, 2026 8:44am
white hawk bird flying

Whitehawk swoops in for five ADCs via deal with Biocytogen

Jul 7, 2026 10:40am
ArticlePrimaryImagejpg

Can We Outrun Cancer's Evolution? Why We Need a New Approach

Brought to you by BrYet US, Inc.
Boehringer Ingelheim booth at AACR 2026

Boehringer bags viral vector platform for cancer vaccine R&D

Jul 7, 2026 10:35am
China US flags

US lawmakers focus on China trials risks ‘huge distraction’

Jul 7, 2026 10:30am
Measuring tape on top of cash

Kalohexis plans IPO to bankroll challengers to GLP-1s

Jul 7, 2026 10:21am
More News
Fierce Pharma

Vertex to pay $10B for Crinetics in its largest-ever deal

Jul 7, 2026 8:08am

Fierce Biotech Layoff Tracker 2026: BioCryst, Biogen, & more

Jul 6, 2026 8:00am

Genentech sees 103 layoffs, pens $490M breast cancer collab

Jul 6, 2026 7:30am

Novartis to pay $1.1B upfront for Myricx to expand ADC pipeline

Jul 6, 2026 5:10am